Diffúz nagy B-sejtes limfóma (DLBCL): vizsgálatok itt: Argentína

3 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

• 3. fázisTaking people
  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  Where

  Buenos Aires, Caba., CABA, Mar del Plata, Pilar, Rosario, San Juan, San Miguel de Tucumán

  Életkor

  18 év and over

  People

  1046 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06717347 · EU 2024-515566-13-00
• 2/3. fázisTaking people
  A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

  Where

  Buenos Aites, CABA, Ciudad Autonoma de Buenos Aires, Córdoba, Mar del Plata

  Életkor

  18 év and over

  People

  290 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT05139017 · EU 2022-502646-27-00
• No phaseTaking people
  Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

  Where

  Buenos Aires, Ciudad Autonoma de Buenos Aire, Córdoba, Pilar

  Életkor

  18 év and over

  People

  700 worldwide

  Run by

  AbbVie

  See details and how to joinNCT06830759